Abstract
Oral disintegrating strips containing rizatriptan benzoate, a selective 5-hydroxy tryptamine receptor agonist with anti migraine property, was developed using polyvinyl alcohol, sodium alginate and hydroxyl propyl methylcellulose as the base materials. The analytical and bioanalytical methods were developed and validated using HPLC (PDA and flouroscence detectors). The dissolution study performed on the strips revealed that all the five formulations, release the drug within eight minutes. Under ICH accelerated stability conditions, strips were stable at 40°C and 75% humidity for eight weeks. Furthermore, pharmacokinetic properties of oral strip were compared with rizatriptan benzoate marketed tablet. Oral disintegrating strip and tablet showed significantly higher bioavailability. Oral strip exhibited better pharmacokinetic parameters than rizatriptan marketed tablet. The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively. These findings confirm that the rizatriptan benzoate oral disintegrating strip is potentially a useful tool for an effective treatment of migraine with improved bioavailability, rapid onset of action and with increased patient compliance.
Keywords: Bioavailability, HPLC, Oral disintegrating strips, Rizatriptan benzoate, Stability.
Current Drug Delivery
Title:Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation
Volume: 13 Issue: 3
Author(s): S. T. Bhagawati, Ankita D. Chonkar, Swapnil J. Dengale, Sreenivasa M. Reddy and Krishnamurthy Bhat
Affiliation:
Keywords: Bioavailability, HPLC, Oral disintegrating strips, Rizatriptan benzoate, Stability.
Abstract: Oral disintegrating strips containing rizatriptan benzoate, a selective 5-hydroxy tryptamine receptor agonist with anti migraine property, was developed using polyvinyl alcohol, sodium alginate and hydroxyl propyl methylcellulose as the base materials. The analytical and bioanalytical methods were developed and validated using HPLC (PDA and flouroscence detectors). The dissolution study performed on the strips revealed that all the five formulations, release the drug within eight minutes. Under ICH accelerated stability conditions, strips were stable at 40°C and 75% humidity for eight weeks. Furthermore, pharmacokinetic properties of oral strip were compared with rizatriptan benzoate marketed tablet. Oral disintegrating strip and tablet showed significantly higher bioavailability. Oral strip exhibited better pharmacokinetic parameters than rizatriptan marketed tablet. The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively. These findings confirm that the rizatriptan benzoate oral disintegrating strip is potentially a useful tool for an effective treatment of migraine with improved bioavailability, rapid onset of action and with increased patient compliance.
Export Options
About this article
Cite this article as:
T. Bhagawati S., D. Chonkar Ankita, J. Dengale Swapnil, M. Reddy Sreenivasa and Bhat Krishnamurthy, Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation, Current Drug Delivery 2016; 13 (3) . https://dx.doi.org/10.2174/15672018113109990048
DOI https://dx.doi.org/10.2174/15672018113109990048 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Mechanism-Based Inhibitors from Phytomedicine: Risks of Hepatotoxicity and their Potential Hepatotoxic Substructures
Current Drug Metabolism Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal
Cardiovascular & Hematological Agents in Medicinal Chemistry Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy Pain and Child: A Translational Hypothesis on the Pathophysiology of a Mild Type-2 Diabetes Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
Current Alzheimer Research Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Drug Targets in Rhinoviral Infections
Infectious Disorders - Drug Targets GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology Molecule of the Month
Current Topics in Medicinal Chemistry Diuretic-Associated Electrolyte Disorders in the Elderly: Risk Factors, Impact, Management and Prevention
Current Drug Safety Psoriasis in Children: A Review
Current Pediatric Reviews